CD8A and cancer: Considering its capacity to boost the cytotoxic activity of CD8+ T cells and NK cells, IL-21 demonstrated therapeutic activity in preclinical animal models and recently progressed to phase 2 of clinical trials for the treatment of cancer (15, 41, 77, 89).